



(12) Oversettelse av  
europeisk patentskrift

(11) NO/EP 2885397 B1

NORGE

(19) NO

(51) Int Cl.

**C12N 1/20 (2006.01)**

**A61K 39/00 (2006.01)**

**A61K 39/102 (2006.01)**

**C12P 19/04 (2006.01)**

## Patentstyret

(21)	Oversettelse publisert	2018.10.08
(80)	Dato for Den Europeiske Patentmyndighets publisering av det meddelte patentet	2018.05.30
(86)	Europeisk søknadsnr	13744668.8
(86)	Europeisk innleveringsdag	2013.07.02
(87)	Den europeiske søknadens Publiseringsdato	2015.06.24
(30)	Prioritet	2012.07.02, FR, 1256329
(84)	Utpekte stater	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Innehaver	Sanofi Pasteur, 14 espace Henry Vallée, 69007 Lyon, FR-Frankrike
(72)	Oppfinner	LE HIR, Jérôme, 36 rue des Filatiers, F-31000 Toulouse, FR-Frankrike LOUBIERE, Pascal, 9 chemin de Pellegri, F-31450 Donneville, FR-Frankrike BARBIRATO, Fabien, 5 rue Victor Hugo, F-69530 Brignais, FR-Frankrike LINDLEY, Nicholas, La Vergnerie basse, F-81310 Parisot, FR-Frankrike
(74)	Fullmektig	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

---

(54)	Benevnelse	<b>METHOD FOR PRODUCING HAEMOPHILUS INFLUENZAE TYPE B ANTIGENS</b>
(56)	Anførte publikasjoner	WO-A2-2009/007641, S YERUVA ET AL: "SCREENING OF MEDIUM COMPONENTS FOR POLYRIBOSYL RIBITOL PHOSPHATE PRODUCTION BY HAEMOPHILUS INFLUENZAE TYPE-B USING PLACKETT-BURMAN DESIGN", JOURNAL OF CELL AND TISSUE RESEARCH, vol. 10, no. 3, 2010, pages 2349-2352, XP055061494,, QU JUN ET AL: "Proteomic expression profiling of Haemophilus influenzae grown in pooled human sputum from adults with chronic obstructive pulmonary disease reveal antioxidant and stress responses", BMC MICROBIOLOGY, BIOMED CENTRAL LTD, GB, vol. 10, no. 1, juin 2010 (2010-06), page 162, XP021073045, ISSN: 1471-2180, DOI: 10.1186/1471-2180-10-162, MERRITT J ET AL: "Development and scale-up of a fed-batch process for the production of capsular polysaccharide from Haemophilus influenzae", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 81, no. 2-3, 25 août 2000 (2000-08-25), pages 189-197, XP004210490, ISSN: 0168-1656, DOI: 10.1016/S0168-1656(00)00320-5, WO-A1-00/56365

Vedlagt foreligger en oversettelse av patentkravene til norsk. I hht patentloven § 66i gjelder patentvernet i Norge bare så langt som det er samsvar mellom oversettelsen og teksten på behandlingsspråket. I saker om gyldighet av patentet skal kun teksten på behandlingsspråket legges til grunn for avgjørelsen. Patentdokument utgitt av EPO er tilgjengelig via Espacenet (<http://worldwide.espacenet.com>), eller via søkemotoren på vår hjemmeside her: <https://search.patentstyret.no/>

## Method for producing *Haemophilus influenzae* type b antigens

The present invention relates to a process for producing, on an industrial scale, capsular polysaccharides of *Haemophilus influenzae* type b (Hib), according to which  
5 a strain of Hib is cultured in a particular culture medium, the composition of which is chemically defined and which therefore comprises no complex source of nitrogen or of carbon.

The prior art, and in particular application W2009/007641, describes improved culture media for *Haemophilus influenzae* type b, which do not comprise any element from an  
10 animal source, as is recommended when the purpose of the culture of *Haemophilus influenzae* type b is to produce capsular polysaccharide which will subsequently be introduced as an antigen into the composition of a vaccine. In the media described in this prior art, the source of nitrogen usually consisting of animal peptones is replaced with plant peptones.

15 Such media represent great progress in terms of the safety of pharmaceutical products with regard in particular to the elimination of the risk of transmission of diseases such as bovine spongiform encephalitis; they therefore make it possible to comply with Health Authority recommendations.

However, the composition of the peptones can vary according to the batches provided,  
20 which can lead to variations in the amounts of bacteria produced and also in the yields of antigens of interest, which vaccine producers try to limit or to correct by modifying certain parameters during the implementation of the process. However, in the context of the industrial production of a pharmaceutical product, it is desirable to be able to have available robust processes which require as few modifications as possible at each  
25 implementation, and the results of which at each step are reproducible from one batch to another.

Such processes must also allow yields that are compatible with industrial profitability, the criterion not being, in the case of production of antigens from bacteria, to obtain solely the largest possible amount of bacteria, but also to obtain the best ratio between  
30 the antigen titer and the amount of bacteria produced; it is therefore desirable for the bacterium to be cultured under conditions which direct its metabolism toward the production of capsular polysaccharide.

- 2 -

To this end, a subject of the present invention is a process for producing, on an industrial scale, capsular polysaccharide of *Haemophilus influenzae* type b (PRP) intended for vaccine purposes, according to which a strain of *Haemophilus influenzae* type b (Hib) is cultured in a culture medium, and the culture supernatant is harvested  
5 and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least:

- one source of carbon,
- protoporphyrin,
- salts,
- 10 – amino acids,
- NAD or NADH,
- vitamins,
- pH-regulating means,

characterized in that said culture medium is chemically defined, and comprises at least  
15 zinc, in an amount corresponding to the amount between 2.5 and 80 mg/l of  $\text{ZnSO}_4 \cdot 7 \text{H}_2\text{O}$ , and in that the PRP/LPS weight ratio is greater than that obtained in the same medium containing no zinc.

By virtue of the invention, it is possible both to have a robust industrial process and to  
20 increase the production of capsular polysaccharide, without having to increase the biomass accordingly, thereby making it possible to reduce the amount of lipopolysaccharides (LPSs) produced relative to the amount of PRP produced.

In addition, the absence of proteins in the composition of the culture medium reduces  
25 the required needs in terms of antifoam product and simplifies the purification step which makes it possible, from the culture supernatant, to obtain the antigen consisting of the capsular polysaccharide.

According to the invention, the culture medium comprises pH-regulating means. These  
30 pH-regulating means can consist of buffer salts and/or of pH-measuring means combined with means for adding either an acid or a base to the medium. The yields can be optimized through the regulation of the pH.

- 3 -

According to one embodiment, the process according to the invention also consists in conjugating the PRP produced to a carrier protein, such as the tetanus protein.

5 A subject of the invention is also a process for preparing a vaccine composition, according to which:

- an antigen against *Haemophilus influenzae* type b (Hib), consisting of the capsular polysaccharide (PRP), is prepared, on an industrial scale, according to the process of the invention for producing PRP,
- the capsular polysaccharide is conjugated to a carrier protein.

10

According to one embodiment, the conjugate obtained is also combined with at least one or more antigens intended for vaccination against one or more of the following infections: diphtheria, tetanus, polio, hepatitis B, chicken pox, mumps, rubella, infections caused by *Neisseria meningitidis* or *Streptococcus pneumoniae*, infections  
15 caused by rotavirus, in order to obtain a vaccine combination which allows simultaneous immunization against several diseases.

According to the process of the invention, the culture medium is chemically defined, i.e. the chemical structure and also the amount of each of the constituents are known.  
20 Such a medium is free of complex source of nitrogen or of carbon, such as peptones, caseins, sera or the like, and can therefore, if desired, be guaranteed to contain no element directly originating from an animal.

The invention relates to a process for producing, on an industrial scale, capsular polysaccharide of *Haemophilus influenzae* type b. Such a process makes it possible to  
25 obtain yields of biomass and of capsular polysaccharides or PRPs which are compatible with industrial constraints. Such a process makes it possible in particular to obtain, from a strain of *Haemophilus influenzae* type b which has in its genetic code at least 2 copies of the *cap* locus encoding the functions enabling capsular synthesis,  
30 without particular regulation of the medium (such as pH or pO<sub>2</sub>), a biomass corresponding to an O.D. at 694 nm of at least 2.4, after 12 hours of culture, and an associated amount of PRP of at least 240 mg/liter of culture medium. The determination of the amount of PRP produced is measured by means of a high-

- 4 -


performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) technique (Dionex), or a method which gives equivalent results. Advantageously, the process according to the invention makes it possible to obtain an amount of PRP of at least 270 mg/liter of medium, and even more advantageously an amount of at least 300 mg/liter.

Among the possible sources for the carbon, mention may be made of all those which can be metabolized by the strain of *Haemophilus influenzae* type b, and in particular: glucose, fructose, galactose, glycerol, xylose, ribose, fucose, sialic acid and lactate. It is also possible to use 2 or more different sources, in particular lactate and glucose.

According to the invention, the amount of glucose present in the starting medium is between 5 and 25 g/l, more particularly from 10 to 20 g/l, and more particularly from 12 to 16 g/l.

The amount of lactate present in the starting medium may be between 0 and 15 g/l, and more particularly from 0.5 to 10 g/l.

According to one embodiment of the invention, the protoporphyrin of the medium is synthetic protoporphyrin, for example the one provided by the company Sigma-Aldrich under reference 258385 (Protoporphyrin disodium salt). Thus, it is possible to use a medium that can be guaranteed to be completely free of substance of animal origin. Alternatively, synthetic protoporphyrin IX is used, the formula of which is the following:



- 5 -

where R denotes H, or a counterion, preferably a counterion of an alkali metal, in particular sodium.

Such a protoporphyrin IX, and the method for preparing same, have been described in patent application FR 2 914 302.

- 5 According to the invention, the amount of protoporphyrin present in the starting medium is advantageously between 0.1 and 10 mg/l, and more particularly between 0.25 and 2 mg/l.

10 The culture medium according to the process of the invention comprises salts which provide the minerals necessary for cell growth, which make it possible to ensure an osmotic pressure favorable to the bacteria, and which also exert a buffering capacity on the pH.

Preferably, use is made of a mixture of monovalent cations such as  $\text{Na}^+$  and/or  $\text{K}^+$ , of divalent cations such as  $\text{Ca}^{++}$ ,  $\text{Mg}^{++}$ ,  $\text{Co}^{++}$ ,  $\text{Zn}^{++}$ ,  $\text{Mn}^{++}$ ,  $\text{Fe}^{++}$ , of phosphate anions in  $\text{HPO}_4^-$ ,  $\text{H}_2\text{PO}_4^-$  and/or  $\text{PO}_4^{--}$  form and of  $\text{SO}_4^-$  and  $\text{Cl}^-$  anions in the form of saline solutions, the molarities of each of which can usually vary within a concentration range of from  $10^{-4}$  mM to 1000 mM.

The salts present in the culture medium are in particular chosen from:  
 $\text{K}_2\text{HPO}_4$ ;  $\text{KH}_2\text{PO}_4$ ;  $\text{MgSO}_4 \cdot 7 \text{H}_2\text{O}$ ;  $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ ;  $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$ ;  $\text{CaCl}_2 \cdot 2$   
 20  $\text{H}_2\text{O}$ ;  $\text{FeSO}_4 \cdot 7 \text{H}_2\text{O}$ ;  $\text{ZnSO}_4 \cdot 7 \text{H}_2\text{O}$ ;  $\text{CoCl}_2 \cdot 6 \text{H}_2\text{O}$ ;  $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ .

The salt concentrations are chosen in order to have an osmolarity of between 200 and 700 milliosmol/l, in particular between 300 and 400 milliosmol/l, especially 350 milliosmol/l, and a pH ranging from 6.5 to 7.5.

25 For this, the culture medium according to the process of the invention can comprise in particular:

- $\text{MgSO}_4 \cdot 7 \text{H}_2\text{O}$  at a concentration of between 150 and 1500 mg/l,
- $\text{CaCl}_2 \cdot 2 \text{H}_2\text{O}$  at a concentration of between 6.5 and 52 mg/l,
- $\text{FeSO}_4 \cdot 7 \text{H}_2\text{O}$  at a concentration of between 1.25 and 10 mg/l,
- 30 -  $\text{ZnSO}_4 \cdot 7 \text{H}_2\text{O}$  at a concentration of between 2.5 and 80 mg/l,
- $\text{CoCl}_2 \cdot 6 \text{H}_2\text{O}$  between 0.5 and 2 mg/l,
- $\text{MnSO}_4 \cdot \text{H}_2\text{O}$  between 2.5 and 10 mg/l,

- 6 -

- sodium in the form in particular of sodium lactate at 60% in an amount of between 0 and 4 ml/l,
  - $K_2HPO_4$  and  $KH_2PO_4$  at a concentration of, for each of them, between 100 and 1200 mg/liter when the buffer effect is provided by  $Na_2HPO_4 \cdot 12 H_2O$  /  $NaH_2PO_4 \cdot 2 H_2O$ ,
  - $Na_2HPO_4 \cdot 12 H_2O$  at a concentration of between 15 and 120 g/l,
  - $NaH_2PO_4 \cdot 2 H_2O$  at a concentration from 10 to 30 times lower than  $Na_2HPO_4 \cdot 12 H_2O$ .
- 10 Alternatively, it is possible for the buffer effect to be provided by the pair  $K_2HPO_4$  /  $KH_2PO_4$ ; in this case, the  $K_2HPO_4$  concentration is between 15 and 120 g/l, and the  $KH_2PO_4$  concentration is from 10 to 30 times lower than that of  $K_2HPO_4$ ; the concentration of  $Na_2HPO_4 \cdot 12 H_2O$  and of  $NaH_2PO_4 \cdot 2 H_2O$  can then be between 100 and 1200 mg/liter.
- 15 Among the salts mentioned, it has been possible to note that the presence of zinc is particularly advantageous for the production of biomass and of PRP, in particular in a concentration ranging from 2.5 to 80 mg/l, or more particularly from 5 to 20 mg/l. Very good results have been obtained at a concentration of 20 mg/l.
- 20 In the case where the pH of the culture medium is regulated during the culture phase, by the addition in particular of a highly concentrated base such as NaOH or KOH, it is possible to reduce the amount of salts present in the medium, and in particular the amount of the buffer pairs  $Na_2HPO_4/NaH_2PO_4$ , or  $K_2HPO_4/ KH_2PO_4$ , provided, however, that the osmolarity is maintained at a suitable value, i.e. between 200 and
- 25 700 mOsm/l, through an optional addition of NaCl.

According to the process of the invention, the culture medium also comprises NAD or a source of NAD, or of any other equivalent coenzyme. NAD (or  $\beta$ -nicotinamide adenine dinucleotide), also called coenzyme I or factor V, is a growth factor essential

30 to the culture of *Haemophilus influenzae* type b. It is advantageously present at a concentration of between 0.5 and 50 mg/l, and more particularly between 2 and 10 mg/l, in particular 5 mg/l of culture medium. It can be introduced into the medium in its NADH reduced form. Alternatively to NAD, the culture medium can comprise



- 7 -

NAD precursor elements that the bacteria will be capable of using, such as NADP/NADPH ( $\beta$ -nicotinamide adenine dinucleotide phosphate) or NMN ( $\beta$ -nicotinamide adenine mononucleotide) or NR (nicotinamide riboside), 3-acetylpyridine adenine dinucleotide (APAD) or 3-acetylpyridine mononucleotide (APMN).

According to the process of the invention, the culture medium contains amino acids which are advantageously chosen from: arginine, alanine, lysine, histidine, tryptophan, valine, isoleucine, leucine, tyrosine, phenylalanine, cystine (or an equivalent), asparagine, glutamine, aspartic acid and glutamic acid.

One formulation of the culture medium comprises arginine, alanine, histidine, tryptophan, tyrosine, phenylalanine, cystine, aspartic acid and glutamic acid only. Alternatively, all of the amino acids mentioned are present in the culture medium.

According to one particular mode, the cystine is replaced with glutathione or cysteine.

According to one preferred embodiment, the process according to the invention uses a culture medium free of the following amino acids: L- methionine, L-glycine, L- proline, L-serine and L-threonine. This is because the presence of these amino acids resulted in an increase in the biomass, but not in a corresponding increase in PRP production.

The amino acids are supplied in the form of very pure powders supplied by Sigma. Particularly advantageously, these amino acids have a synthetic origin or have been obtained by virtue of processes which guarantee the fact that they contain no element originating directly from an animal, in order to exclude any risk of contamination by transmissible infections, and in particular by BSE (Bovine Spongiform Encephalitis).

The amounts of each amino acid are chosen in order to optimize cell growth and PRP production. The amounts of aspartic acid, of asparagine and of glutamine are chosen so as to cause a deficiency during the cell culture, thereby making it possible to direct the metabolism of the cell towards the production of capsular polysaccharide, while the amounts of the other amino acids are chosen such that there is no deficiency during the culture phase.

- 8 -

According to the process of the invention, the culture medium also contains vitamins which are chosen from: thiamine, pantothenate, uracil, hypoxanthine, biotin, riboflavin and pyridoxine. For the purposes of the invention, the term "vitamins" also encompasses uracil and hypoxanthine which are nitrogenous bases.

- 5 Particularly advantageously, the vitamins present in the culture medium have a non-animal origin, in particular a synthetic origin, thereby making it possible to exclude any risk of contamination by transmissible infections, and in particular by BSE (Bovine Spongiform Encephalitis). Use is in particular made of vitamins supplied by Sigma, the degree of purity of which is accurately known, thereby enabling a very  
10 accurate dosage during the preparation of the culture medium.

The amounts of vitamins present in the medium are chosen in order to optimize the production of biomass and of PRP.

- According to one particular mode of the invention, the culture medium comprises  
15 citrulline which can substitute for arginine and for uracil.

In this case, the amount of citrulline included in the culture medium is advantageously between 150 and 500 mg/l.

- By virtue of the culture medium according to the process of the invention, it has been  
20 possible to produce Polyribosyl Ribitol Phosphate in greater amount than when media according to the prior art are used, while at the same not consuming more carbohydrate, and not producing more contaminant, in particular LPS.

- According to one embodiment of the invention, the strain of *Haemophilus influenzae*  
25 type b cultured is an encapsulated strain which has at least 2 copies of the *cap* locus in its genetic code. This *cap* locus, between 17 and 18 kb in size, groups together genes of which the expression is linked to the synthesis and the exportation of the capsule.

- The expression of the capsule gives the bacteria a white color when it is cultured on specific agar; the colonies of bacteria which have this *cap* locus are consequently  
30 called "white colonies", whereas the bacteria which do not export the capsular polysaccharide to the surface of the capsule are called "gray colonies". The expression of the capsule is subject to potential genetic instability, which can lead to the appearance of capsule-deficient mutants, which would consequently lead to a decrease

in PRP production. Studies have made it possible to demonstrate that the chemically defined medium used in the process according to the invention makes it possible to ensure good genetic stability of the strain used during about twenty cell generations.

- 5 According to the invention, it is possible to perform the culture of the *Haemophilus influenzae* type b bacterium in several successive steps so as to gradually increase the biomass.

In this case, the bacteria originating from a lyophilisate or from a frozen sample are inoculated into a volume of medium which generally does not exceed 1 liter. After  
10 culture overnight or when the optical density of the medium is sufficient, this first culture is transferred into a second culture medium identical to the first, but the volume of which may be up to 10 to 20 times greater. The amount of bacteria inoculated into the second medium is adjusted such that the initial optical density (O.D.) of the second culture medium at 694 nm is between 0.2 and 0.4 so as to promote rapid growth of the  
15 bacterial population. This second culture is usually performed in a fermentor, but other types of containers can be used (flasks, spinners, etc). When the culture is performed in a fermentor, a temperature of 37°C +/- 1°C, constant stirring, a pressure of 0.1 bar, a pO<sub>2</sub> of 30% and an air flow rate of 0.25 volume of gas per volume of medium per minute are normally used for the duration of the culture. It is within the competence of  
20 those skilled in the art to choose other parameters for this type of culture. At the end of the exponential bacterial growth phase, the biomass can be further amplified by transferring it into another fermentor of larger capacity using the same procedure and so on. The culture volumes obtained can reach, or even exceed, 1000 liters. The culture(s) is (are) generally performed according to the "batchwise" mode.

- 25 Finally, the supernatant of the final culture is taken after inactivation of the bacteria. The inactivation is conventionally carried out using a solution of formol at a final concentration of 0.35%-0.37% (V/V). The supernatant is conventionally separated from the bacteria by means of a centrifugation step. The PRP contained in the resulting supernatant is then extracted and purified according to conventional processes well  
30 known to those skilled in the art.

The PRP harvested and purified is then advantageously conjugated to a carrier protein such as the tetanus protein, in order to make it T-dependent and to enable in particular the immunization of young children. The PRP-T antigen thus obtained can then be

- 10 -

used alone in a monovalent vaccine, or be combined with other antigens in order to enable simultaneous vaccination against several diseases.

Particularly advantageously, the present invention provides a process for preparing a vaccine composition, according to which the conjugate obtained is combined with at least one or more antigens usually present in pediatric vaccines, and in particular antigens against diphtheria, tetanus, poliomyelitis, hepatitis B, infections caused by *Neisseria meningitidis* or par *Streptococcus pneumoniae*, chicken pox, mumps, rubella, infections caused by a rotavirus, etc.

According to one embodiment, the PRP-T conjugate is present in powder form, whereas the other antigens are in liquid form, all of the antigens being mixed extemporaneously before administration; according to one alternative embodiment, the vaccine composition is entirely liquid.

The preparation process according to the invention thus makes it possible to prepare a quadrivalent vaccine combination comprising, in addition to the PRP-T conjugate, diphtheria, tetanus and hepatitis B antigens. Alternatively, it makes it possible to prepare a quadrivalent vaccine combination comprising, in addition to the PRP-T conjugate, diphtheria toxoid, tetanus toxoid, and 2 acellular Bordetella pertussis antigens (toxoid and filamentous hemagglutinin) or 3 acellular Bordetella pertussis antigens (the previous two + pertactin) or else 5 acellular Bordetella pertussis antigens (the previous three + the agglutinogens).

It also makes it possible to prepare a pentavalent vaccine combination comprising, in addition to the PRP-T conjugate, diphtheria toxoid, tetanus toxoid, 2, 3 or 5 acellular Bordetella pertussis antigens and also inactivated type 1, 2 and 3 polioviruses.

It also makes it possible to prepare a hexavalent vaccine combination comprising, in addition to the PRP-T conjugate, diphtheria toxoid, tetanus toxoid, 2, 3 or 5 acellular Bordetella pertussis antigens, hepatitis B and also inactivated type 1, 2 and 3 polioviruses. Such a hexavalent combination can in particular be liquid and can comprise, per 0.5 ml dose:

- diphtheria toxoid in amount of 20 IU,
- tetanus toxoid in amount of 40 IU,
- the hepatitis B surface antigen in a proportion of 10 µg,
- pertussis toxoid in a proportion of 25 µg,

- 11 -

- pertussis filamentous hemagglutinin in a proportion of 25 µg,
- PRP-T in a proportion of 12 µg of PRP,
- inactivated type 1, 2 and 3 polioviruses in a respective amount of 40, 8 and 32 DU,
- 5       - aluminum hydroxide in a proportion of 0.6 mg of Al<sup>3+</sup>.

Alternatively, it makes it possible to prepare vaccine combinations in which the whooping cough antigens consist of the whole *Bordetella pertussis* bacterium.

- 10    By virtue of the culture process according to the invention, it is possible to increase the production of Polyribosyl Ribitol Phosphate, without increasing the amount of biomass, thereby making it possible to reduce the amount of contaminating LPSs; this advantage of the process according to the invention is very important to the vaccine industry, where these products are introduced into vaccine compositions as antigens
- 15    and where the amounts of LPSs must be reduced to a minimum. Having available a process which makes it possible not to increase the amount of LPS produced for a greater amount of PRP offers the possibility of simplifying the subsequent purification process.

20    Example 1: Preparation of a culture medium according to the process of the invention

A culture medium according to the process of the invention was prepared from a basic medium to which enrichment solutions were added extemporaneously.

- 25    The composition of the basic medium is indicated in table I below:

Table I:

Compounds	Amounts in    mg for 1 l	supplier	product ref.
60% sodium lactate	1.5 ml	Prolabo	27925.292
K <sub>2</sub> HPO <sub>4</sub>	300	VWR	26931.263

- 12 -

		Prolabo	
KH <sub>2</sub> PO <sub>4</sub>	300	VWR Prolabo	26923.298
MgSO <sub>4</sub> .7H <sub>2</sub> O	368	VWR Prolabo	25165.260
Na <sub>2</sub> HPO <sub>4</sub> .12H <sub>2</sub> O	28620	VWR Prolabo	28028.298
NaH <sub>2</sub> PO <sub>4</sub> . 2H <sub>2</sub> O	1870	VWR Prolabo	28015.294
L-Arginine	87	Sigma	A5006 or A8094
L-Alanine	134	Sigma	A7627 or A7469 or A4349
L-Asparagine	198	Sigma	A0884 or A7094
L-Lysine	140	Sigma	L5626 or L8662 or L7039
L-Glutamine	220	Sigma	G3126 or G8540 or G5792
L-Histidine	78	Sigma	H8000 or H6034 or H3911
L-Tryptophan	200	Sigma	T0254 or T8941 or T4196
L-Valine	115	Sigma	V0500 or V0513 or V4638
L-Isoleucine	130	Sigma	I2752 or

- 13 -

			I7403 or I5281
L-Leucine	130	Sigma	L8000 or L6914 or L8912
L-Tyrosine	180	Sigma	T3754 or T8566 or T4321
L-Phenylalanine	165	Sigma	P5482
L-Cystine	61	Sigma	C8755 or C7602 or C5735
L-aspartic acid	1065	Sigma	A9256 or A5474
L-glutamic acid	1471	Sigma	G1251 or G8415
Pyridoxine HCl	4	Sigma	P5669
Riboflavin	0.2	Sigma	R4500
Thiamine HCl	4	Sigma	T4625
Biotin	4	Sigma	B4501
Ca Pantothenate	4.5	Sigma	P5710
Uracil	70	Sigma	U0750
Hypoxanthine	20	Sigma	H9377
FeSO <sub>4</sub> .7H <sub>2</sub> O	2.5	Aldrich	450278
ZnSO <sub>4</sub> .7H <sub>2</sub> O	5	Sigma	Z4750
CoCl <sub>2</sub> . 6H <sub>2</sub> O	1	Fluka	60818
MnSO <sub>4</sub> . H <sub>2</sub> O	5	Sigma	M7634
CaCl <sub>2</sub> . 2H <sub>2</sub> O	13	Panreac	131232.1211

To prepare 1 liter of medium, the various compounds were added, in the order described in the table above, to approximately 100 ml of demineralized water, with

- 14 -

stirring using a magnetic bar. Before addition, all the powders had been previously dissolved in a small volume of demineralized water with, in certain cases, the addition of acid or of base.

Thus, for the valine, isoleucine and leucine, it was necessary to add, to the amounts indicated in the table, 140  $\mu$ l of 10 N KOH; to the tyrosine, it was necessary to add 280  $\mu$ l of 10 N KOH; to the phenylalanine, it was necessary to add 210  $\mu$ l of 37% HCl, and to the cystine, it was necessary to add 70  $\mu$ l of 37% HCl.

Finally, the pH was adjusted to  $7.2 \pm 0.1$  with 10 N KOH (in the event of the pH having been too high, 37% HCl would have been used), then demineralized water was used to make the volume up to the desired amount.

The medium was then sterilized by means of filtration on a filter having a cut-off threshold at 0.22  $\mu$ m.

It was thus possible to store the medium for 72 hours at 5°C.

15

Before the inoculation of the medium, the following were added:

- 27.3 ml of glucose at 512.8 g/l prepared from anhydrous D(+) glucose supplied by the company VWR under the reference 24379.294,
- 5 ml of a solution of NAD at 1 g/l, supplied by the company Sigma under the name  $\beta$ -Nicotinamide Adenine Dinucleotide hydrate (ref. 43410),
- 4 ml of a stock solution comprising protoporphyrin at the concentration of 0.25 g/l and ammonium hydroxide at the concentration of 5 ml/l; the protoporphyrin being supplied by the company Sigma Aldrich under the name Protoporphyrin IX disodium salt (ref. 258385) and the ammonium hydroxide by the company VWR under the name Ammonia solution 28% (ref. 21190.292),

20

25

in order to obtain 1 liter of medium ready to be inoculated, and comprising, in addition to the elements described in table I above, the following additional elements with the concentrations as indicated in table II below:

30 Table II:

Compounds	Concentration before inoculation in the medium
Protoporphyrin	1 mg/l



- 15 -

Aqueous ammonia	17.7 µg/l
Anhydrous glucose	14 g/l
NAD	5 mg/l

Example 2: Preparation of a culture medium according to the prior art

- 5 A culture medium according to the prior art was prepared by adding specific enrichment solutions to a basic medium.

The composition of the basic medium is indicated in table III below:

Table III:

Compounds	Concentration in the basic medium
Pea peptone	7.42 g/l
60% Sodium Lactate	1.5 ml/l
Na <sub>2</sub> HPO <sub>4</sub> .12H <sub>2</sub> O	31.14 g/l
NaH <sub>2</sub> PO <sub>4</sub> . 2H <sub>2</sub> O	2.03 g/l
Cystine (L)	0.07 g/l
HCl (10N)	0.07 ml/l
Tryptophan (L)	0.02 g/l
(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	1 g/l
MgSO <sub>4</sub> . 7H <sub>2</sub> O	0.4 g/l
CaCl <sub>2</sub> . 2H <sub>2</sub> O	0.02 g/l

- 10 To prepare this basic medium, each of the elements was added, in the order in which they are indicated in the table, to 100 ml of demineralized water continuously stirred using a magnetic bar. Each of the elements, supplied in powder form, had previously been dissolved in a small volume of demineralized water.

- The pea peptone comes from the company Kerry and is sold under the reference Hy-  
 15 pea 7404. The (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> is supplied by the company VWR under the reference 21333.296. The other elements come from the same suppliers and are supplied under the same references as those described in example 1 for the preparation of the medium according to the process of the invention.

- 16 -

The final pH was adjusted to  $7.2 \pm 0.1$  with 10 N KOH (in the event of the pH having been too high, 37% HCl would have been used).

Demineralized water was then added in order to obtain the desired volume, and then it was sterilized by autoclaving, according to a cycle of 30 minutes at 120°C.

- 5 Once sterilized, the medium could be stored for 15 days at 4°C.

The enrichment solutions A, B, C and D were added to this basic medium.

- 10 The solution A is a solution comprising anhydrous glucose at the concentration of 512.8 g/l, supplied by the company VWR under the name anhydrous D(+) glucose (ref. 24379.294).

The solution B is a stock solution comprising NAD at the concentration of 1 g/l, supplied by the company Sigma under the name  $\beta$ -Nicotinamide Adenine Dinucleotide hydrate (ref. 43410).

- 15 The solution C is a stock solution comprising protoporphyrin at the concentration of 0.25 g/l and ammonium hydroxide at the concentration of 5 ml/l; the protoporphyrin being supplied by the company Sigma Aldrich under the name Protoporphyrin IX disodium salt (ref. 258385) and the ammonium hydroxide by the company VWR under the name Ammonia solution 28% (ref. 21190.292).

- 20 The solution D is a concentrated solution comprising autolytic yeast extract ultrafiltrate (Ufel) at 125 g/l; it is supplied by the company Biospringer under the name Ultrafiltrat d'extrait autolytique de levure (Ufel) [Autolytic yeast extract ultrafiltrate] (Ref. springer 0701).

- 25 Each of these solutions is sterilized by filtration on a filter of which the cut-off threshold is 0.22  $\mu$ m.

The following were added to 1 liter of basic medium:

- 30
- 35.1 ml of solution A
  - 5 ml of solution B
  - 4 ml of solution C
  - 40 ml of solution D.

The addition of each of the solutions to the basic medium was carried out under a laminar flow hood and resulted in a culture medium having, before inoculation, in addition to the elements mentioned in table III above, the following additional elements in the concentration indicated in table IV below:

5

Table IV:

<b>Compounds</b>	<b>Concentration before inoculation in the medium</b>
Autolytic yeast extract ultrafiltrate (Ufel)	4.9 g/l
Protoporphyrin	1 mg/l
Aqueous ammonia	17.7 µg/l
Anhydrous glucose	18 g/l
NAD	5 mg/l

10

Example 3: Comparison of PRP production with a medium according to the process of the invention as described in example 1 and a medium of the prior art as described in example 2

- 15 These comparative experiments were carried out according to a 2-step culture protocol:
- a step of preculture in a non-baffled 1-liter glass Erlenmeyer flask, at 36°C with stirring at 130 rpm (revolutions per minute), for a period of 8 hours, at the end of which the strain is at the end of the linear growth phase; this preculture is initiated by inoculating 280 ml of culture medium with an
  - 20 inoculum of bacteria of *Haemophilus influenzae* type b containing at least 2 copies of the *cap* locus, at a concentration of 0.5% (volume/volume);
  - then a transfer of 90 ml of the preculture made it possible to inoculate a 2-liter Biostat B plus fermentor containing 1.8 liters of culture medium. This fermentor was maintained at 37°C, with stirring at 400 rpm, with an
  - 25 aeration of 0.45 lpm (liter per minute) for 12 hours.

After 12 hours of culture, the O.D. at 694 nm was measured, which made it possible to determine the biomass. This is because, during previous tests, it was possible to determine that one unit of optical density measured at 694 nm corresponded to 0.64 g of biomass (dry mass)/liter.

The amount of total PRP in the culture supernatant was determined by high-performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD), according to a method very similar to that described in the publication by Sturgess *et al.* (Vaccine 17 (1999) 1169-1178). The culture supernatant was filtered by passing it through a 0.22  $\mu$ m filter, and then 500  $\mu$ l of supernatant were ultrafiltered via the use of Amicon ultra columns with a cut-off threshold of 10 kDa (Millipore ref. UFC5010BK) and then subjected to a basic hydrolysis step by adding NaOH.

The hydrolysis was carried out at ambient temperature for a minimum of 4 hours.

The validity of the assay was controlled by using an internal standard, glucosamine-1-phosphate (GlcN1P), present in the hydrolysis solution, and by regularly passing through an internal control having a known PRP concentration. With respect to the indications of Sturgess *et al.*, the mobile phase was composed of 35 mM NaOH and 114 mM CH<sub>3</sub>COONa and the regeneration phase was carried out for 10 minutes with 100 mM NaOH and 400 mM CH<sub>3</sub>COONa.

The results obtained are indicated in table V below:

Table V:

	<b>Medium according to the invention (4 tests)</b>	<b>Medium of the prior art (1 test)</b>
O.D. at 694 nm	2.52 $\pm$ 0.14	3.9
Biomass in g of dry mass/liter of culture medium	1.74 $\pm$ 0.09	2.6
PRP concentration in mg/liter of culture medium	349 $\pm$ 22	169
Specific production in mg of PRP/g of biomass	199 $\pm$ 3	66

These results show the advantage of the process according to the invention for the PRP productivity: it is in fact noted that, for the same volume of culture medium, while the

- 19 -

biomass obtained was greater with a culture medium according to the prior art, the amount of PRP was, on the other hand, smaller.

5 Example 4: Comparison of the amount of PRP and of LPS present in a culture supernatant according to the process of the invention, and in a culture supernatant according to a process of the prior art

The culturing of *Haemophilus influenzae* type b was carried out comparatively with a medium according to the process of the invention and with a medium according to the prior art, in the manner described in example 3, with however the difference that the  
10 basic medium of the process according to the prior art comprised 10 g/l of casein acid hydrolysate supplied by the company Solabia (ref. A1434) in place of the pea peptone present in the medium according to example 3.

The preculture time is, as in example 3, 8 hours, and the culture time is 12 hours.

The assaying of PRP and the assaying of LPS are both carried out by HPAEC-PAD;  
15 but the assaying of LPS is carried out by quantification of a particular monosaccharide, heptose, using a standard range of purified LPS having undergone the same protocol, the internal control for this assay being rhamnose.

The results obtained are indicated in table VI below:

Table VI:

	<b>Medium according to the invention (4 tests)</b>	<b>Medium according to the prior art (3 tests)</b>
OD at 694 nm	2.5 ± 0.1	3.9 ± 0.3
Biomass in g of dry mass/l of medium	1.7 ± 0.1	2.5 ± 0.2
LPS concentration in mg/l of medium	5 ± 1	4.6 ± 1
PRP concentration in mg/l of medium	349 ± 22	17 ± 5
PRP/LPS ratio	74 ± 15	38 ± 6

- 20 -

The results obtained show the advantage of the process according to the invention, which makes it possible to reduce the amount of LPSs produced relative to the amount of PRP.

This represents a significant advantage of the process according to the invention, since  
 5 this very much simplifies the purification operations, while at the same time maintaining an appropriate safety level.

#### Example 5: Test for evaluating the importance of zinc

10 The importance of the presence of zinc in the culture medium was studied.

To this effect, 3 media were compared:

- a medium such as that described in example 1, called MS,
- a medium which has a composition identical to that of example 1, but without the ZnSO<sub>4</sub>, called MS Zn-,
- 15 - a medium such as that described in example 1, but with a ZnSO<sub>4</sub> concentration which is 4 times higher, i.e. 20 mg/l, said medium being called MS Zn++.

The media were then sterilized by means of filtration on a filter having a cut-off threshold at 0.22 µm.

A step of preculture in a non-baffled 1-liter glass Erlenmeyer flask was first of all  
 20 performed, for 16 hours at 36°C with stirring at 130 rpm, by inoculating 280 ml of a medium as described in example 4 with a frozen sample of *Haemophilus influenzae* type b bacteria having in the genetic code thereof at least 2 copies of the *cap* locus.

9.5 ml of preculture were then washed in each of the culture media to be tested, before the inoculation for the culture which was performed each time in a baffled 500 ml  
 25 polycarbonate Erlenmeyer flask containing 170 ml of the culture medium to be tested; the culture was performed for 12 hours at 37°C and stirring was performed at 150 rpm.

For each medium, the biomass, the PRP concentration and also the amount of LPS at the end of culture were determined, in the same way as described in examples 3 and 4, and the PRP/biomass and also LPS/biomass and PRP/LPS ratios were calculated.

30 The results obtained are indicated in table VII below:

Table VII:

	MS	MS Zn-	MS Zn++
Biomass in g of dry mass/liter of culture medium	1.98	1.23	2.22

- 21 -

PRP concentration in mg/liter of culture medium	319	203	372
Specific production in mg of PRP/g of biomass	160	165	167
LPS concentration in mg/liter of culture medium	11.5	8.8	12.1
LPS/biomass ratio in mg/g of biomass	6.1	7.2	5.5
PRP/LPS ratio in mg/mg	30	23	31

These results showed that the presence of zinc in the culture medium makes it possible to significantly increase the production of biomass and also the production of PRP, without, however, proportionally increasing the amount of LPS

5

#### Example 6: Tests in a 5-liter fermentor

The culturing of *Haemophilus influenzae* type b was carried out in the culture medium described according to the invention in example 1, using only products guaranteed by the suppliers to be animal-free and using synthetic protoporphyrin as described in patent application FR 2 914 302, and supplied by the company Solvias AG under the name: Protoporphyrin IX Disodium Salt (Ref. SOL20402). The tests were then carried out in the manner described in example 3, with the exception that the fermentors used were 5-liter fermentors regulated at 37°C, with stirring at 550 rpm and aeration at 0.5 lpm. The inoculum volume was then 280 ml, i.e. the entire preculture Erlenmeyer flask.

15

The PRP and LPS concentration was determined according to the protocols described in examples 3 and 4.

20 The results obtained are indicated in table VIII below:

Table VIII:

	<b>Animal-free medium according to the invention</b>
O.D. at 694 nm	3.58
Biomass in g of dry mass/l of medium	2.29

- 22 -

PRP concentration in mg/l of medium	567
Specific production in mg of PRP/g of biomass	247

These results confirm the previous results, and show the advantage of the process according to the invention for obtaining a large amount of PRP.

5 Example 7: Comparison of the production of biomass and of PRP with a medium according to the invention as described in example 1 and with chemically defined media described in the prior art

10 The culturing of *Haemophilus influenzae* type b was carried out in the culture medium described according to the invention in example 1 and also in 8 media described in publications in connection with the culture of *Haemophilus influenzae*, and presented as being chemically defined.

These 8 media were prepared according to the recommendations of the authors. They are, in chronological order, the media of:

- 15       - Talmadge and Herriott: Biochemical and Biophysical Research Communications, (March 1960), Vol.2 N°3, p 203-206),
- Butler: J. gen. Microbiol. (1962), 27, 51-60,
- Wolin: J. Bacteriol. Vol.85, (1963) Notes, p 253-254,
- 20       - Herriott *et al.* : Journal of Bacteriology, (Feb. 1970), Vol. 101, N°2, 513-516,
- Klein and Luginbuhl: Journal of General Microbiology (1979), 113, 409-411
- Coleman *et al.* : Journal of Clinical Microbiology, (Sept 2003), Vol.41, N°9 p. 4408-4410.

25 The references of the products used to prepare these 8 media are reproduced in table IX below:

Table IX:

Products	Suppliers	product ref.
----------	-----------	--------------



- 23 -

Uridine	Sigma	U3003
Inosine	Sigma	I4125
Adenosine	Sigma	A4036
Guanine	Sigma	G6779
Guanosine	Sigma	G6264
Vitamine B12	Sigma	V2876
Citrulline	Sigma	C7629
Choline chloride	Fluka	26978
Thimidine	Sigma	T9250
Inositol	Sigma	I5125
Putrescine dihydrochloride	Sigma	P5780
Nicotinamide	Sigma	N0636
Porcine hematin	Sigma	H3281
Hemin	Fluka	51280
Sodium oleate	Sigma	O7501
Sodium acetate	Fluka	71185
Folic acid	Sigma	F7876
Polyvinyl alcohol	Sigma	341584
Triethanolamine	Sigma	90278
Glycylglycine buffer	Libios	B-GLYGLY250
Tween 40	Sigma	P1504
Tween 80	Sigma	P1754
Tris buffer	VWR	33621.260
ethylenediaminetetraacetate	VWR	20302.180
HEPES	Sigma	H3375
Glutathione	Sigma	G6013
Adenine	Sigma	A8626
Proline	Sigma	P0380
Threonine	Sigma	T8625
Glycine	Sigma	G7126
Methionine	Sigma	M9625
Serine	Sigma	S4500

- 24 -

Glycerol	VWR	24387.292
K <sub>2</sub> SO <sub>4</sub>	VWR	26994.293
KCl	VWR	26764.298
MgCl <sub>2</sub> . 6H <sub>2</sub> O	Panreac	131396.1211
NaCl	VWR	27810.295
NaHCO <sub>3</sub>	VWR	27778.260
NH <sub>4</sub> Cl	VWR	21236.291
RPMI 1640 with L-glutamine and 25 mM HEPES	Invitrogen	former ref. cited in the publication by Coleman (2003) ref. 61870036 => new ref. 52400025
Sodium pyruvate MEM 100 mM	Invitrogen	former ref. cited in the publication by Coleman (2003) ref. 11360070 => new ref. 11360039

The media were then sterilized by means of filtration on a filter having a cut-off threshold at 0.22 µm.

5 A step of preculture in a non-baffled 1-liter glass Erlenmeyer flask was first of all carried out, for 16 hours at 36°C with stirring at 130 rpm, by inoculating 280 ml of a medium as described in example 4 with a frozen sample of *Haemophilus influenzae* type b bacteria having in the genetic code thereof at least 2 copies of the *cap* locus.

9.5 ml of preculture were then washed in each of the culture media to be tested, before the inoculation for the culture which was performed each time in a baffled 500 ml  
10 polycarbonate Erlenmeyer flask containing 170 ml of the culture medium to be tested; the culture was performed for 12 hours at 37°C and stirring at 150 rpm.

Each test was carried out at least 3 times.

For each medium, each hour, the O.D. at 694 nm was measured and the PRP concentration was determined at the end of culture, in the same way as described in  
15 example 3.

The O.D. results are reproduced in figure 1.

The results of the PRP determinations are indicated in table X below:

Table X:

- 25 -

at 12 h	O.D. at 694 nm	PRP (mg/l)
Medium according to the invention	$2.86 \pm 0,12$	$320 \pm 15$
Talmadge	$0.28 \pm 0,10$	$20 \pm 1$
Butler	$0.04 \pm 0,00$	$2 \pm 0$
Wolin	$0.04 \pm 0,00$	$6 \pm 0$
Herriot Mic-cit	$1.26 \pm 0,15$	$138 \pm 7$
Herriot Mic	$0.98 \pm 0,13$	$101 \pm 5$
Klein MMA (cit)	$0.38 \pm 0,01$	$40 \pm 2$
Klein MMB	$0.20 \pm 0,03$	$27 \pm 1$
Coleman	$1.43 \pm 0,04$	$204 \pm 10$

#### Example 8: Industrial-scale PRP production (1000 liters)

A culture medium according to the invention having the composition of example 1, except for the zinc, where the concentration is 20 mg/l instead of 5 mg/l, was prepared. This is because example 5 showed that this concentration made it possible to produce more PRP without increasing the amount of LPS.

The medium was identical for the precultures and the final culture, except the pH (initial pH  $7.2 \pm 0.1$ , then free pH for the precultures and pH regulated at  $6.7 \pm 0.1$  for the production culture).

10

The medium was prepared as in example 1. After having mixed the compounds previously dissolved in a small volume of purified water, with, in certain cases, the addition of acid or of base (cf. example 1), and before adding the sufficient quantity of purified water, the pH was adjusted to  $7.2 \pm 0.1$  for the precultures and  $6.7 \pm 0.1$  for the final culture (with 10 N potassium hydroxide or sodium hydroxide or 37% HCl).

15

The medium was then sterilized by means of filtration on a filter having a cut-off threshold at  $0.22 \mu\text{m}$ .

It was thus possible to store the medium for 72 hours at  $5^\circ\text{C}$ .

Before the inoculation of the medium, the following were added:

- 26 -

- glucose at 512.8 g/l prepared from anhydrous D(+) glucose supplied by the company VWR under the reference 24379.294,
- a solution of NAD at 1 g/l, supplied by the company Sigma under the name  $\beta$ -Nicotinamide Adenine Dinucleotide hydrate (ref. 43410),
- 5       - a stock solution comprising protoporphyrin at the concentration of 0.25 g/l and ammonium hydroxide at the concentration of 5 ml/l; the protoporphyrin being supplied by the company Solvias AG under the name Protoporphyrin IX disodium salt (ref. SOL20402) and the ammonium hydroxide by the company VWR under the name Ammonia solution 28% (ref. 21190.292),
- 10    in order to obtain a medium ready to be inoculated, and comprising, in addition to the elements described in table I of example 1, the additional elements with the concentrations as indicated in table II of example 1 (except the glucose at a final concentration of 14.87 g/l instead of 14 g/l).
- 15    The 1000-liter scale process comprised a series of 3 precultures:
  - the first precultures were performed in a non-baffled 1-liter Erlenmeyer flask containing 290 ml of complete culture medium, at 37°C with stirring at 130 rpm (revolutions per minute), for a period of 17-18 hours. These precultures were initiated by inoculating the culture medium with an inoculum of *Haemophilus influenzae* type b
  - 20    bacteria containing at least 2 copies of the *cap* locus, with an inoculation level corresponding to an initial target OD<sub>694 nm</sub> of 0.014;
  - the second preculture series was performed in a 6.8-liter fermentor. Two fermentors containing 5.2 liters of complete culture medium were each inoculated with 260 ml of
  - 25    a preculture of series 1. These fermentors were maintained for 4 hours at 37°C  $\pm$  1, with an initial pH at 7.2  $\pm$  0.2, a pO<sub>2</sub> maintained at 30% with a cascade involving an increase in the stirring (500 to 800 rpm), then an increase in the aeration (0.5 to 2.5 lpm) and then a flow rate of pure O<sub>2</sub> between 0 and 6 lpm;
  - 30    - the third preculture series was performed in a 120-liter fermentor containing 57 liters of complete medium which was inoculated with 5.8 liters of the preculture originating from series 2. This fermentor was maintained for 3 hours 10 at 37°C  $\pm$  1, with an initial pH of 7.2  $\pm$  0.2, a pO<sub>2</sub> maintained at 30% with a cascade involving an increase

- 27 -

in the stirring (300 to 425 rpm), then an increase in the aeration (6 to 28 lpm) and then a flow rate of pure O<sub>2</sub> between 0 and 50 lpm.

The industrial culture was performed in a 1000-liter fermentor containing 778 liters of complete medium which was inoculated with 39 liters of a preculture of series 3. This fermentor was maintained at 32°C ± 1, with a pH regulated at 6.7 ± 0.2 (with a 2.5 N sodium hydroxide solution), a pO<sub>2</sub> maintained at 70% by virtue of a cascade involving an increase in the stirring (100 to 230 rpm), then an increase in the aeration (70 to 150 lpm) and then a flow rate of pure O<sub>2</sub> between 0 and 500 lpm. Moreover, antifoam (Biospumex at 4%) was added on demand depending on the foam level.

After 12 hours of culture, the O.D. at 694 nm was measured, which made it possible to determine the biomass (according to the correspondence of one OD unit corresponding to 0.64 g of dry biomass). The PRP and LPS concentration was determined according to the protocols described in examples 3 and 4.

The results obtained are indicated in table XI below:

Table XI:

	<b>Medium according to the invention (1 test)</b>
O.D. at 694 nm	3.45
Biomass in g of dry mass/liter of culture medium	2.21
PRP concentration in mg/liter of culture medium	865
Specific production in mg of PRP/g of biomass	392
LPS concentration in mg/liter of culture medium	35.6
LPS/biomass ratio in mg/g of biomass	16.1
PRP/LPS ratio in mg/mg	24.3

These results showed the advantage of the process according to the invention for the PRP productivity and the PRP/LPS ratio, said results having been demonstrated on an industrial scale.

**Patentkrav**

- 5    **1.** Fremgangsmåte for å fremstille, i industriell skala, kapsulært polysakkarid av *Haemophilus influenzae* type b (PRP) beregnet for vaksineformål, ifølge hvilket en stamme av *Haemophilus influenzae* type b (Hib) dyrkes i et kulturmedium, og kultursupernatanten høstes og behandles for å ekstrahere kapselpolysakkaridet derfra, idet dyrkingsmediet omfatter minst:
- 10    - en kilde til karbon,  
- protoporfyrin,  
- salter,  
- aminosyrer,  
- NAD eller NADH,
- 15    - vitaminer,  
- pH-regulerende midler,
- karakterisert ved at** dyrkingsmediet er kjemisk definert, og omfatter i det minste sink, i en mengde som tilsvarer mengden mellom 2,5 og 80 mg/l  $\text{ZnSO}_4 \cdot 7 \text{H}_2\text{O}$ , og **ved at** PRP/LPS-vektforholdet er større enn det som oppnås i det samme mediet som ikke
- 20    inneholder sink.
- 2.** Fremgangsmåte ifølge det foregående kravet, **karakterisert ved at** det pH-regulerende midlet består av buffersalter.
- 25    **3.** Fremgangsmåte ifølge ett av de foregående kravene, **karakterisert ved at** kilden til karbon kan være mangfoldig og er valgt fra: glukose, fruktose, galaktose, glyserol, xylose, ribose, fukose, sialinsyre og laktat.
- 4.** Fremgangsmåte ifølge ett av de foregående kravene, **karakterisert ved at**
- 30    protoporfyrinet er syntetisk protoporfyrin IX.
- 5.** Fremgangsmåte ifølge ett av de foregående kravene, **karakterisert ved at** saltene er valgt fra kalium-, magnesium-, natrium-, kalsium-, jern-, sink-, kobolt- og mangansalter.
- 35    **6.** Fremgangsmåte ifølge det foregående kravet, **karakterisert ved at** saltene er valgt fra:  $\text{K}_2\text{HPO}_4$ ;  $\text{KH}_2\text{PO}_4$ ;  $\text{MgSO}_4 \cdot 7 \text{H}_2\text{O}$ ;  $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ ;  $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$ ;  $\text{CaCl}_2 \cdot 2 \text{H}_2\text{O}$ ;  $\text{FeSO}_4 \cdot 7 \text{H}_2\text{O}$ ;  $\text{ZnSO}_4 \cdot 7 \text{H}_2\text{O}$ ;  $\text{CoCl}_2 \cdot 6 \text{H}_2\text{O}$ ;  $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ .

**7.** Fremgangsmåte ifølge ett av de foregående kravene, **karakterisert ved at** aminosyrene er valgt fra:

- arginin,
- alanin,
- 5 • minst én valgt blant: asparagin, glutamin, asparaginsyre, glutaminsyre,
- lysin,
- histidin,
- tryptofan,
- valin,
- 10 • isoleucin,
- leucin,
- tyrosin,
- fenylalanin,
- cystin eller tilsvarende.

15 **8.** Fremgangsmåte ifølge det foregående kravet, **karakterisert ved at** dyrkingsmediet omfatter minst arginin, alanin, histidin, tryptofan, tyrosin, fenylalanin, cystin, asparaginsyre og glutaminsyre.

20 **9.** Fremgangsmåte ifølge ett av de foregående kravene, **karakterisert ved at** cysteiniet erstattes med glutation eller cystein.

**10.** Fremgangsmåte ifølge ett av de foregående kravene, **karakterisert ved at** vitaminene er valgt fra: tiamin, pantotenat, uracil, hypoksantin, biotin, riboflavin og  
25 pyridoksin.

**11.** Fremgangsmåte ifølge ett av de foregående kravene, **karakterisert ved at** argininet og uracilet erstattes med citrullin.

30 **12.** Fremgangsmåte for fremstilling av en vaksinesammensetning, ifølge hvilken:  
- a) et antigen mot *Haemophilus influenzae* type b (Hib), som består av kapselpolysakkaridet (PRP), fremstilles, i industriell skala, ifølge fremgangsmåten ifølge krav 1,  
- b) kapselpolysakkaridet oppnådd i trinn a) konjugeres til et bærerprotein.

35 **13.** Fremgangsmåte ifølge det foregående kravet, **karakterisert ved at** bærerproteinet er tetanustoksoid.

**14.** Fremgangsmåte ifølge ett av kravene 12 og 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med minst ett eller flere antigener som vanligvis er til stede i barnevaksiner.

5

**15.** Fremgangsmåte for fremstilling av en vaksinesammensetning ifølge krav 12 eller 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med difteri, tetanus og hepatitt-B-antigener.

10 **16.** Fremgangsmåte for fremstilling av en vaksinesammensetning ifølge krav 12 eller 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med difteritoksoid, tetanustoksoid og 2 acellulære *Bordetella pertussis*-antigener, som er toksoid og filamentøst hemagglutinin.

15 **17.** Fremgangsmåte for fremstilling av en vaksinesammensetning ifølge krav 12 eller 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med difteritoksoid, tetanustoksoid og 3 acellulære *Bordetella pertussis*-antigener, som er toksoid, pertaktin og filamentøst hemagglutinin.

20 **18.** Fremgangsmåte for fremstilling av en vaksinesammensetning ifølge krav 12 eller 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med difteritoksoid, tetanustoksoid og 5 acellulære *Bordetella pertussis*-antigener, som er toksoid, pertaktin, agglutino gener og filamentøst hemagglutinin.

25 **19.** Fremgangsmåte for fremstilling av en vaksinesammensetning ifølge krav 12 eller 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med difteritoksoid, tetanustoksoid, 2, 3 og 5 acellulære *Bordetella pertussis*-antigener, og også inaktiverte poliovirus av type 1, 2 og 3.

30 **20.** Fremgangsmåte for fremstilling av en vaksinesammensetning ifølge krav 12 eller 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med difteritoksoid, tetanustoksoid, hepatitt-B-antigener 2, 3 og 5 acellulære *Bordetella pertussis*-antigener, og også inaktiverte poliovirus av type 1, 2 og 3.

35 **21.** Fremgangsmåte for fremstilling av en vaksinesammensetning ifølge krav 12 eller 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med hele *Bordetella pertussis*-bakterien.



**22.** Fremgangsmåte for fremstilling av en vaksinesammensetning ifølge krav 12 eller 13, **karakterisert ved at** konjugatet oppnådd i trinn b) kombineres med minst én av antigenene mot difteri, tetanus, poliomyelitt, hepatitt B, infeksjoner forårsaket av *Neisseria meningitidis* eller av *Streptococcus pneumoniae*.

